Published in Ann Surg Oncol on January 20, 2010
Pancreatic cancer. Lancet (2004) 11.63
Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell (2012) 3.39
Recent progress in pancreatic cancer. CA Cancer J Clin (2013) 2.88
The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy for adenocarcinoma. Ann Surg Oncol (2014) 1.58
Integrative survival-based molecular profiling of human pancreatic cancer. Clin Cancer Res (2012) 1.33
Resectable pancreatic small cell carcinoma. Rare Tumors (2011) 1.11
Applying next-generation sequencing to pancreatic cancer treatment. Nat Rev Gastroenterol Hepatol (2012) 1.04
Molecular characteristics of pancreatic ductal adenocarcinoma. Patholog Res Int (2011) 1.03
Therapeutic options for the management of pancreatic cancer. World J Gastroenterol (2014) 0.96
Overexpression of GOLPH3 is associated with poor prognosis and clinical progression in pancreatic ductal adenocarcinoma. BMC Cancer (2014) 0.93
Radiotherapy and erlotinib combined: review of the preclinical and clinical evidence. Front Oncol (2012) 0.93
Impact of adjuvant radiotherapy on survival after pancreatic cancer resection: an appraisal of data from the national cancer data base. Ann Surg Oncol (2013) 0.92
Palliative surgical management of patients with unresectable pancreatic adenocarcinoma: trends and lessons learned from a large, single institution experience. J Gastrointest Surg (2011) 0.89
Resection margins in pancreatic cancer. Pathologe (2013) 0.87
Adjuvant chemoradiation therapy after pancreaticoduodenectomy in elderly patients with pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys (2010) 0.87
Multivariate analysis of immunohistochemical evaluation of protein expression in pancreatic ductal adenocarcinoma reveals prognostic significance for persistent Smad4 expression only. Cell Oncol (Dordr) (2012) 0.86
Adjuvant chemoradiation for pancreatic cancer: what does the evidence tell us? J Gastrointest Oncol (2014) 0.86
Analysis of local control in patients receiving IMRT for resected pancreatic cancers. Int J Radiat Oncol Biol Phys (2012) 0.85
Pancreatic cancer metastasis: are we being pre-EMTed? Curr Pharm Des (2015) 0.85
Challenges in the study of adjuvant chemoradiation after pancreaticoduodenectomy. Ann Surg Oncol (2010) 0.83
Preliminary results of hyperthermic intraperitoneal intraoperative chemotherapy as an adjuvant in resectable pancreatic cancer. Gastroenterol Res Pract (2012) 0.82
Effect of chemoradiotherapy and neoadjuvant chemoradiotherapy in resectable pancreatic cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol (2013) 0.82
Loco-recurrence after resection for ductal adenocarcinoma of the pancreas: predictors and implications for adjuvant chemoradiotherapy. J Cancer Res Clin Oncol (2012) 0.82
Pattern of breast cancer susceptibility gene 1 expression is a potential prognostic biomarker in resectable pancreatic ductal adenocarcinoma. Pancreas (2013) 0.81
Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine. Methods Mol Biol (2013) 0.80
Lymph node ratio and preoperative CA 19-9 levels predict overall survival and recurrence-free survival in patients with resected pancreatic adenocarcinoma. World J Gastrointest Oncol (2012) 0.80
Chemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question? Contemp Oncol (Pozn) (2016) 0.79
Meta-analyses of treatment standards for pancreatic cancer. Mol Clin Oncol (2015) 0.79
53BP1 expression is a modifier of the prognostic value of lymph node ratio and CA 19-9 in pancreatic adenocarcinoma. BMC Cancer (2013) 0.79
Neoadjuvant chemoradiotherapy has a potential role in pancreatic carcinoma. Ther Adv Med Oncol (2011) 0.79
A Multidisciplinary Approach to Pancreas Cancer in 2016: A Review. Am J Gastroenterol (2017) 0.79
The influence of adjuvant radiotherapy dose on overall survival in patients with resected pancreatic adenocarcinoma. Cancer (2013) 0.78
Risk Factors Associated with Loco-Regional Failure after Surgical Resection in Patients with Resectable Pancreatic Cancer. PLoS One (2016) 0.78
Adjuvant radiation therapy for pancreatic cancer: a review of the old and the new. J Gastrointest Oncol (2015) 0.77
Clinical Management of Pancreatic Cancer. J Adv Pract Oncol (2015) 0.75
Adjuvant and neoadjuvant systemic therapy for pancreas adenocarcinoma. Semin Oncol (2014) 0.75
Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer (2016) 0.75
Aggressive secondary surgery for local recurrence of pancreatic cancer. BMJ Case Rep (2013) 0.75
Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma. World J Surg Oncol (2015) 0.75
Number of evaluated lymph nodes and positive lymph nodes, lymph node ratio, and log odds evaluation in early-stage pancreatic ductal adenocarcinoma: numerology or valid indicators of patient outcome? World J Surg Oncol (2016) 0.75
Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma. Chin J Cancer Res (2015) 0.75
Adjuvant chemoradiotherapy for resected pancreas cancer. World J Gastrointest Surg (2010) 0.75
Pancreatic Cancer: 80 Years of Surgery-Percentage and Repetitions. HPB Surg (2016) 0.75
Adjuvant therapy for pancreas cancer in an era of value based cancer care. Cancer Treat Rev (2015) 0.75
Radiosensitizers in pancreatic cancer--preclinical and clinical exploits with molecularly targeted agents. Curr Probl Cancer (2013) 0.75
Neoadjuvant radiotherapeutic strategies in pancreatic cancer. World J Gastrointest Oncol (2016) 0.75
Intraductal Papillary Mucinous Adenocarcinoma of the Pancreas: Clinical Outcomes, Prognostic Factors, and the Role of Adjuvant Therapy. Viszeralmedizin (2015) 0.75
The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer. Expert Rev Anticancer Ther (2012) 0.75
Prognostic value of splenic artery invasion in patients undergoing adjuvant chemoradiotherapy after distal pancreatectomy for pancreatic adenocarcinoma. Cancer Res Treat (2014) 0.75
Biological determinants of radioresistance and their remediation in pancreatic cancer. Biochim Biophys Acta (2017) 0.75
Evolving treatment landscape for early and advanced pancreatic cancer. World J Gastrointest Oncol (2017) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med (2001) 18.77
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA (2007) 14.54
Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med (2001) 13.75
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med (2004) 13.34
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg (1985) 7.14
Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg (1990) 7.04
One thousand consecutive pancreaticoduodenectomies. Ann Surg (2006) 6.59
Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg (1993) 6.15
Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet (2001) 5.75
Improved hospital morbidity, mortality, and survival after the Whipple procedure. Ann Surg (1987) 5.58
Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol (2008) 4.34
Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg (1997) 3.90
Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol (2008) 3.51
Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol (2008) 3.45
Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer (1987) 3.24
Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). J Clin Oncol (2008) 3.15
Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg (2003) 3.13
Advanced statistics: the propensity score--a method for estimating treatment effect in observational research. Acad Emerg Med (2004) 1.78
Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation +/- 5 fluorouracil. Int J Radiat Oncol Biol Phys (1993) 1.71
Adjuvant therapy for pancreatic cancer--the debate continues. N Engl J Med (2004) 1.18
On statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancer. Ann Surg (2006) 1.17
A challenge to the therapeutic nihilism of ESPAC-1. Int J Radiat Oncol Biol Phys (2005) 1.14
The case for adjuvant chemoradiation for pancreatic cancer. Best Pract Res Clin Gastroenterol (2006) 1.12
Continuing controversy over adjuvant therapy of pancreatic cancer. Lancet (2001) 1.11
ESPAC-1 trial of adjuvant therapy for resectable adenocarcinoma of the pancreas. Ann Surg (2002) 0.89
The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg (2009) 16.82
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature (2011) 9.70
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology (2012) 7.22
1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg (2006) 7.18
DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol (2009) 6.43
Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg (2002) 6.24
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol (2011) 6.16
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet (2009) 5.82
Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol (2006) 5.78
Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg (2004) 5.12
Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med (2011) 5.03
Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience. Clin Gastroenterol Hepatol (2006) 4.70
Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA (2008) 4.61
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol (2012) 4.48
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet (2011) 4.38
Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology (2007) 4.33
Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg (2007) 3.73
Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A (2011) 3.51
Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol (2008) 3.51
Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery (2007) 3.42
Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol (2003) 3.40
Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med (2004) 3.39
Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell (2012) 3.39
Gallbladder cancer: the role of laparoscopy and radical resection. Ann Surg (2007) 3.38
Assessment of complications after pancreatic surgery: A novel grading system applied to 633 patients undergoing pancreaticoduodenectomy. Ann Surg (2006) 3.35
Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res (2004) 3.31
Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis. Gastroenterology (2010) 3.24
Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res (2003) 3.23
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol (2007) 3.19
Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg (2009) 3.15
Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). J Clin Oncol (2008) 3.15
Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer. Ann Surg Oncol (2008) 3.14
Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol (2006) 3.01
Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis. Hepatology (2014) 2.98
New staging system and a registry for perihilar cholangiocarcinoma. Hepatology (2011) 2.89
Recent progress in pancreatic cancer. CA Cancer J Clin (2013) 2.88
Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother (2013) 2.80
Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology (2002) 2.76
Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer. Am J Gastroenterol (2007) 2.73
MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res (2013) 2.71
Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol (2006) 2.66
Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg (2008) 2.66
Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol (2003) 2.63
Surgical management of bile duct injuries sustained during laparoscopic cholecystectomy: perioperative results in 200 patients. Ann Surg (2005) 2.58
Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res (2003) 2.49
Laparoscopic distal pancreatectomy is associated with significantly less overall morbidity compared to the open technique: a systematic review and meta-analysis. Ann Surg (2012) 2.48
Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys (2008) 2.45
SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res (2009) 2.44
Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol (2007) 2.44
Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol (2002) 2.44
Is there a difference in survival between right- versus left-sided colon cancers? Ann Surg Oncol (2008) 2.43
Expanding criteria for resectability of colorectal liver metastases. Oncologist (2008) 2.39
Risk factors and outcomes in postpancreaticoduodenectomy pancreaticocutaneous fistula. J Gastrointest Surg (2004) 2.35
Hepatic resection for colorectal metastases: value for risk scoring systems? Ann Surg (2007) 2.35
Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. Am J Pathol (2002) 2.35
Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol (2009) 2.35
Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network. Lancet Oncol (2006) 2.32
Patient readmission and mortality after colorectal surgery for colon cancer: impact of length of stay relative to other clinical factors. J Am Coll Surg (2012) 2.29